All In MedTech

Device Trial Radar · NCT06560177

Biolinq External Interferent Protocol

Acetaminophen Interferent Evaluation of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Sep 10, 2024

Primary completion

Sep 27, 2024

Study completion Sep 27, 2024

Sponsor

Lead sponsor
Biolinq Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 19, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the interference effect of acetaminophen (APAP) on the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System during a single in-clinic day on Day 3 of the sensor wear period. All participants will be asked to wear the Biolinq System and a commercial CGM comparator for three days while taking fingersticks on a commercial Self-Monitoring Blood Glucose Meter. All participants will come back to the clinic on the third day of sensor wear for an in-clinic day which will include blood draws and fingersticks to compare glucose measurements to a Lab Analyzer. At the end of the in clinic day the subjects will have the sensors removed and then exit the study.

Conditions

  • Diabetes
  • Diabetes Mellitus

Interventions

  • The Biolinq MicroArray Intradermal Continuous Glucose Biowearable SystemDevice

    All participants will wear 1 Biolinq System on volar forearm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Samples Where YSI Values Matched the Biolinq Sensor's Color During the First Hour Post Acetaminophen (APAP) Intake.Time frame: First hour post Acetaminophen (APAP) intake

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.